Samuraciclib (hydrochloride)

• Description:

  Samuraciclib hydrochloride (CT7001 hydrochloride) is a potent, selective, ATP-competitive and orally active CDK7 inhibitor, with an IC50 of 41 nM. Samuraciclib hydrochloride displays 45-, 15-, 230- and 30-fold selectivity over CDK1, CDK2 (IC50 of 578 nM), CDK5 and CDK9, respectively. Samuraciclib hydrochloride inhibits the growth of breast cancer cell lines with GI50 values between 0.2-0.3 µM. Samuraciclib hydrochloride has anti-tumor effects[1][2].

• Product Name Alternative:

  CT7001 (hydrochloride) ; ICEC0942 (hydrochloride)

• UNSPSC:

  12352005

• Hazard Statement:

  H302, H315, H319, H335

• Target:

  Apoptosis; CDK

• Type:

  Reference compound

• Related Pathways:

  Apoptosis; Cell Cycle/DNA Damage

• Applications:

  Cancer-Kinase/protease

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/CT7001_hydrochloride.html

• Purity:

  99.98

• Solubility:

  DMSO : 100 mg/mL (ultrasonic) |H2O : 55 mg/mL (ultrasonic)

• Smiles:

  O[C@H]1CNCC[C@@H]1CNC2=NC3=C (C (C) C) C=NN3C (NCC4=CC=CC=C4) =C2.[H]Cl

• Molecular Formula:

  C22H31ClN6O

• Molecular Weight:

  430.97

• Precautions:

  H302, H315, H319, H335

• References & Citations:

  [1]Hazel P, et al. Inhibitor Selectivity for Cyclin-Dependent Kinase 7: A Structural, Thermodynamic, and Modelling Study. ChemMedChem. 2017 Mar 7;12 (5) :372-380.|[2]Patel H, et al. ICEC0942, an Orally Bioavailable Selective Inhibitor of CDK7 for Cancer Treatment. Mol Cancer Ther. 2018 Jun;17 (6) :1156-1166.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  4°C (Powder, stored under nitrogen, away from moisture)

• Scientific Category:

  Reference compound1

• Clinical Information:

  Phase 2

• Isoform:

  CDK1; CDK2; CDK4; CDK5; CDK6; CDK7; CDK9

• Citation 01:

  Adv Sci (Weinh) . 2024 Dec 10:e2413103.|Biochem Biophys Res Commun. 2024 Aug 28:735:150608.|Cell Death Dis. 2019 Aug 9;10 (8) :602.|Clin Cancer Res. 2024 May 1;30 (9) :1889-1905.|Proc Natl Acad Sci U S A. 2019 Jun 25;116 (26) :12986-12995. |Res Sq. 2024 Jul 29.|Structure. 2024 Jun 9:S0969-2126 (24) 00188-6.|EMBO J. 2025 Sep 8.|Int J Mol Sci. 2022 Feb 24;23 (5) :2493.|J Cancer Res Clin Oncol. 2023 Jul;149 (8) :5255-5263.|mBio. 2025 Dec 10;16 (12) :e0289825.|Signal Transduct Target Ther. 2025 Nov 6;10 (1) :363.

• CAS Number:

  1805789-54-1